6-fluoro-4-oxo-7-pyrrolidin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | 116169-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-fluoro-4-oxo-7-pyrrolidin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
• 英文别名: 6-Fluoro-1,4-dihydro-4-oxo-7-(1-pyrrolidinyl)-1,8-naphthyridine-3-carboxylic acid；6-fluoro-4-oxo-7-pyrrolidin-1-yl-1H-1,8-naphthyridine-3-carboxylic acid
• CAS: 116169-47-2
• 化学式: C₁₃H₁₂FN₃O₃
• 分子量: 277.255
• InChiKey: WAQPXPPRAVOEPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  82.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,6-dichloro-α-(ethoxymethylene)-5-fluoro-β-oxo-3-pyridinepropanoic acid ethyl ester 在 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 4.0h， 生成 6-fluoro-4-oxo-7-pyrrolidin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  在尝试合成吡啶并ze庚酮羧酸时遇到的重排。

  摘要：

  尝试通过标准方法合成吡啶基ze庚酮羧酸（如33）仅导致异常和意想不到的重排产物。尝试通过六元环的扩环和羟醛环的闭合来形成七元环。在每种情况下，主要产品都是由于未检测到所需产品而对原料进行了重排而产生的。最终，制备了吡啶并ze庚酮乙酯的异构体。然而，尝试皂化导致了另一种异常的重新排列。[反应：看文字]

  DOI：

  10.1021/ol0481378

文献信息

• Antibacterial compounds
  申请人：——

  公开号：US20030232818A1

  公开（公告）日：2003-12-18

  Antibacterials having formula (I) 1 and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

  抗菌剂的化学式（I）及其盐、前药、前药的盐，制备这些化合物的方法和用于制备过程中使用的中间体，含有这些化合物的组合物，以及使用这些化合物进行细菌感染的预防和治疗方法被披露。
• Novel inhibitors of bacterial protein synthesis: structure–activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants
  作者：Richard F. Clark、Sanyi Wang、Zhenkun Ma、Moshe Weitzberg、Christopher Motter、Michael Tufano、Rolf Wagner、Yu-Gui Gu、Peter J. Dandliker、Claude G. Lerner、Linda E. Chovan、Yingna Cai、Candace L. Black-Schaefer、Linda Lynch、Douglas Kalvin、Angela M. Nilius、Steve D. Pratt、Niru Soni、Tianyuan Zhang、Xiaolin Zhang、Bruce A. Beutel

  DOI：10.1016/j.bmcl.2004.03.091

  日期：2004.6

  Structure-activity relationships for a recently discovered novel ribosome inhibitor (NRI) class of antibacterials were investigated. Preliminary efforts to optimize protein synthesis inhibitory activity of the series through modification of positions 3 and 4 of the naphthyridone lead template resulted in the identification of several biochemically potent analogues. A lack of corresponding whole cell antibacterial activity is thought to be a consequence of poor cellular penetration as evidenced by the enhancement of activity observed for a lead analogue tested in the presence of a cell permeabilizing agent. (C) 2004 Elsevier Ltd. All rights reserved.
• Novel Antibacterial Class:  A Series of Tetracyclic Derivatives
  作者：Mira M. Hinman、Teresa A. Rosenberg、Darlene Balli、Candace Black-Schaefer、Linda E. Chovan、Douglas Kalvin、Philip J. Merta、Angela M. Nilius、Steve D. Pratt、Niru B. Soni、Frank L. Wagenaar、Moshe Weitzberg、Rolf Wagner、Bruce A. Beutel

  DOI：10.1021/jm060010w

  日期：2006.8.1

  We describe the synthesis and antibacterial activity of a series of tetracyclic naphthyridones. The members of this series act primarily via inhibition of bacterial translation and belong to the class of novel ribosome inhibitors (NRIs). In this paper we explore the structure-activity relationships (SAR) of these compounds to measure their ability both to inhibit bacterial translation and also to inhibit the growth of bacterial cells in culture. The most active of these compounds inhibit Streptococcus pneumoniae translation at concentrations of < 5 mu M and have minimum inhibitory concentrations (MICs) of < 8 mu g/mL against clinically relevant strains of bacteria.
• Naphthyridine antibacterial compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0153580B1

  公开（公告）日：1989-01-25
• US8163769B2
  申请人：——

  公开号：US8163769B2

  公开（公告）日：2012-04-24